Investor

Fidelity Biosciences

Last cheque observed Nov 2014. Silence since then is not evidence of inactivity: our sources miss unannounced rounds.

QuietInvestment firm

Series ASeries BSeries C

Cheques on record
0%of best year0cheques in 12 months, 46 on record
Since the last cheque4359days00hrs00min00sec
Median round$21MRounds led0 of 46Exits6 from the portfolioMostly inUnited States, 90%
Pitch Fidelity Biosciences

Fidelity Biosciences highlights

  1. 01

    46 rounds on record

  2. 02

    Mostly Series A and Series B: 61% of its rounds

  3. 03

    6 exits from the portfolio

What they do

Type
Investment firm (from a list, unverified)
Cheque size
Not stated
Cold pitches
Not stated

The record

Every round we can evidence, newest first46 appearances

  1. 2014

    9 rounds

  2. Nov
    NovaerusVenture · US$10MWith 2 others
  3. Oct
    UNUM TherapeuticsSeries A · US$12MWith 3 others
  4. Oct
    Avidity NanoMedicinesSeries B · US$6.0MWith 4 others
  5. Oct
    Aclaris TherapeuticsSeries B · US$21MWith 3 others
  6. Sept
    AdaptimmuneSeries A · GB$104MWith 12 others
  7. Jun
    Dimension TherapeuticsSeries A · US$30MWith 2 others
  8. May
    Coherus BiosciencesSeries C · US$55MWith 9 others
  9. Apr
    Mersana TherapeuticsSeries A · US$15MWith 2 others
  10. Jan
    Blueprint MedicinesSeries B · US$25MWith 5 others
  11. 2013

    8 rounds

  12. Dec
    ViewRayVenture · US$30MWith 5 others
  13. Nov
    PulmocideSeries A · GB · finsmes.com$28MWith 4 others
  14. Oct
    Mersana TherapeuticsSeries A · US · boston.citybizlist.com$5.0MWith 1 other
  15. Sept
    Acacia PharmaSeries B · GB · finsmes.com$24MWith 2 others
  16. May
    ViewRaySeries D · US · pehub.com$15MWith 5 others
  17. Apr
    Iora HealthSeries B · US · finsmes.com$14MWith 4 others
  18. Mar
    US HealthVestSeries A · US · pehub.com$36MWith 5 others
  19. Jan
    KyruusSeries B · US · kyruus.com$11MWith 5 others
  20. 2012

    8 rounds

  21. Dec
    Ultragenyx PharmaceuticalGrowth · US · globenewswire.com$75MWith 6 others
  22. Nov
    Innovent BiologicsSeries B · CN · fiercepharmamanufacturing.com$25MWith 4 others
  23. Oct
    Aclaris TherapeuticsSeries A · US · finsmes.com$21MWith 3 others
  24. Aug
    Procured HealthSeed · US · techcrunch.com$1.1MWith 6 others
  25. Jul
    Mersana TherapeuticsSeries A · US · finsmes.com$27MWith 4 others
  26. Jul
    Ultragenyx PharmaceuticalSeries A · US · bizjournals.com$15MWith 1 other
  27. Apr
    LiazonSeries D · US · liazon.com$18MWith 4 others
  28. Mar
    ViewRaySeries C · US · finsmes.com$45MWith 5 others
  29. 2011

    6 rounds

  30. Oct
    Imagen BiotechSeries A · US · businesswire.com$40MWith 4 others
  31. Sept
    ViewRayVenture · US · wraltechwire.com$10MWith 5 others
  32. Aug
    FluidnetSeries C · US · fluidnet.net$25MWith 5 others
  33. Jun
    Ultragenyx PharmaceuticalSeries A · US · finsmes.com$45MWith 4 others
  34. Apr
    Blueprint MedicinesSeries A · US · blueprintmedicines.com$40MWith 2 others
  35. Jan
    NextWave PharmaceuticalsSeries C · US · finsmes.com$45MWith 7 others
  36. 2010

    5 rounds

  37. Oct
    Accuri CytometersSeries E · US · onbiovc.com$6.0MWith 5 others
  38. Aug
    ViewRaySeries C · US · viewray.com$20MWith 5 others
  39. Jun
    Vicept TherapeuticsSeries A · US · vicepttx.com$16MWith 4 others
  40. Jun
    Foldrx PharmaceuticalsVenture · US · fiercebiotech.com$29MWith 7 others
  41. Jun
    Tetraphase PharmaceuticalsSeries C · US · fiercebiotech.com$45MWith 7 others
  42. 2009

    1 round

  43. Aug
    Accuri CytometersSeries D · US · onbiovc.com$4.0MWith 6 others
  44. 2008

    4 rounds

  45. Aug
    Proteostasis TherapeuticsSeries A · US · sec.gov$71MWith 5 others
  46. Jul
    Accuri CytometersSeries C · US · sec.gov$13MWith 3 others
  47. Jan
    ViewRaySeries B · US$25MWith 3 others

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

Exits from the portfolio

Companies it backed that were later bought or listed6 in all

NextWave PharmaceuticalsBought by PfizerUndisclosedOct 2012
Vicept TherapeuticsBought by Allergan$275MJul 2011
NovaMed PharmaceuticalsBought by SciClone Pharmaceuticals$105MApr 2011
Accuri CytometersBought by (Becton, Dickinson and Company)UndisclosedMar 2011
MicrobiaBought by DSMUndisclosedSept 2010
Foldrx PharmaceuticalsBought by PfizerUndisclosedSept 2010

An exit counts when it came after the firm's first round in the company. From historical deal records.

Who they invest alongside

The investors most often in the same rounds as Fidelity Biosciences. A count of rooms they were both in, not a relationship either has claimed.

F-Prime CapitalVC firm38rounds togetherAisling CapitalPrivate equity8rounds togetherOrbiMedPrivate equity8rounds togetherKearny Venture PartnersVC firm7rounds togetherNew Enterprise AssociatesVC firm5rounds togetherSofinnova InvestmentsVC firm5rounds togetherPolaris PartnersVC firm4rounds togetherSiemensCorporate VC4rounds togetherVivo VenturesVC firm4rounds togetherArboretum VenturesVC firm3rounds togetherCarl ByersAngel3rounds togetherFlagship Pioneering, LLCVC firm3rounds together

Quick answers about Fidelity Biosciences

What does Fidelity Biosciences invest in?

Fidelity Biosciences invests most often at Series A and Series B (61% of the rounds on record).

How active is Fidelity Biosciences?

46 investments on record, 0 of them in the last 12 months. The most recent was in Nov 2014.

How big are Fidelity Biosciences's cheques?

The median round it joins is $21M.

Does Fidelity Biosciences lead rounds?

Rarely, if at all: none of its 46 investments on record names it as the lead.

Where does Fidelity Biosciences invest?

Most of the companies it backs are in the United States (90%) and the United Kingdom (8%).

Is Fidelity Biosciences investing now?

No investments in the last 12 months; the latest was in Nov 2014.

Who does Fidelity Biosciences invest alongside?

Most often F-Prime Capital (38 rounds together), Aisling Capital (8 rounds together) and OrbiMed (8 rounds together).

What kind of investor is Fidelity Biosciences?

Fidelity Biosciences is an investment firm.

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Find similar investorsOpen your CRM

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it